Background and aim ¹¹¹ In-DTPA-octreotide is internalized by thyroid and
Introduction
Follicular and papillary thyroid cancer, so-called differentiated thyroid cancer (DTC), is an uncommon tumor, representing approximately 3% of all neoplasms. The incidence of DTC is 5-10/ 100000 per year and the overall prognosis is good with 10 year survival rates between 92-98% [1;2] . The initial treatment consists of surgery, which is followed by ablation with ¹³¹ I. To assess tumor recurrence and/or metastases, plasma thyroglobulin (Tg) and ¹³¹ I whole body scintigraphy (WBS) are well-established techniques [3;4] . Recurrences and/or metastases can be treated with repeat surgery, ¹³¹ I treatment and/or radiotherapy. However, a number of patients show disease progression, assessed either radiological or by increasing Tg levels, under ¹³¹ I treatment or have WBS scans with no ¹³¹ I uptake. Many reports have focused on the value of fluorodeoxyglucose positron emission tomography (FDG PET) for the detection of metastatic disease in these patients [5] [6] [7] . Iodine negative locoregional disease detected by FDG PET can be treated with surgery or external irradiation, but, despite an improved locoregional control, it does not affect the overall survival [8;9] . Irrespective of the good diagnostic accuracy, there are currently no wellestablished treatment options for patients with ¹³¹ I non-responsive multiple metastases. In such cases, 5 year survival rates decline to 60-82% [10;11] . et al. [13] , a high expression of SST 1, 3, 4 and 5 was found in both papillary thyroid cancer and follicular thyroid adenoma. Medullary thyroid cancer cells showed expression of all subtypes, whereas neuroendocrine tumors express SST 1 and 2 and to a lesser extent SST 5 [14] . The somatostatin analogue octreotide shows high affinity for subtype 2, average affinity for subtypes 3 and 5, and no affinity for SSTs 1 and 4 [15;16] . The expected effect of 111 In-DTPA-octreotide on tumor tissue is based on the internalization of the radiolabeled octreotide through these somatostatin receptors. Once in the cell, short-range Auger electrons emitted by the ¹¹¹In will cause DNA damage. The diagnostic value of 111 In-octreotide in thyroid cancer has already been confirmed in some small case series [17] [18] [19] [20] .
The aim of this study was to observe the effect of high doses of 111 In-DTPAoctreotide therapy in patients with disseminated and progressive radioiodine non-responsive thyroid cancer.
Patients, materials and methods

Patients
Eleven consecutive patients (seven women and four men; mean age, 63 years, Tumor progression before entering this study was based on rising Tg levels ( Figure 1 ) and confirmed by radiological evaluation. To assess the effects during treatment with 111 In-DTPA-octreotide Tg levels were gathered from 2 years before, during and up to 1 year after treatment. Exclusion criteria were a life expectancy <6 months, kidney and liver dysfunction other than caused by metastases and no visible 111 In-octreotide uptake in metastases. The medical ethics committee of our institution approved therapy and all patients gave informed consent.
Baseline characteristics
To assess the octreotide uptake, baseline scans were performed using 220 MBq of 111 In-DTPA-octreotide. Whole body scintigraphy (run speed 10 cm/min) and single photon emission computed tomography (SPECT) of the chest and head and neck region were performed at 4 and 24 h p.i. using a dual-head gamma camera (Toshiba GCA 7200, Japan). The SPECT images (matrix size 128 x 128;
with a 6° step angle and a 1 min step time) were reconstructed using filtered back-projection and a Butterworth pre-processing filter (8 order, 0.12 subset).
These scans were used to exclude patients with no 111 In-DTPA-octreotide uptake from treatment. In this respect, scoring of tumor radioactivity was done visually according to the criteria described by Krenning et al. ranging from 0 to 4 [16] .
All patients underwent a baseline radiological evaluation (computed tomography (CT) or magnetic resonance imaging (MRI) approximately a month before or immediately after the first therapeutic octreotide dose to determine baseline tumor size and extent and number of metastases. A complete biochemical and haematological screening was done for all patients as well as the measurement of Tg-on and thyroid stimulating hormone (TSH) levels.
In-DTPA-octreotide therapy
In this protocol we intended to treat patients with a standard activity of approximately 7400 MBq 111 In-DTPA-octreotide per injection. A complete treatment course was defined as four administrations with an interval between two administrations ranging from 2 to 3 weeks. The treatment dose was adjusted or postponed in case of side effects, as trombocytopenia.
Follow-up
On days 0, 3, 7, 14 and 21 after each 111 In-DTPA-octreotide administration a complete biochemical and haematological screening, including tumor markers and tumor marker antibodies, were performed. In addition, whole body scintigraphy was performed on days 3 and 7 (run speed 20 cm/min) to measure the uptake in at least two metastases during treatment using the procedure described previously [21] . Tg levels were also measured 3 and 9 months after the final ¹¹¹ In-DTPA-octreotide administration, which is approximately 6 and 12 months, respectively, after the first administration. Furthermore, 3 months after the last treatment a CT scan was performed.
Treatment evaluation
Three criteria were used for evaluation: criterion number 1 was a radiographic (CT or MRI) response in which images prior to and 6 months after the first administration were compared. Radiological stable disease was defined as an equalization in tumor size and in number/extent of metastases. Any increase in tumor size or number of metastases was defined as progression. Criteria 2a and 2b were tumor marker response assessed at 3 and 6 months, respectively, after the first administration.
(A) (B) Figure 1 . Post-treatment 131 I whole body scintigraphy (8000MBq) (A) in a 57-year-old man with a history of a T3N0M1 follicular thyroid carcinoma and an increasing thyroglobulin (Tg) level showed a normal, physiological distribution. The accumulation in the pelvic region is physiological excretion into the bladder and rectum. Whole body scintigraphy after the injection of 8000 MBq of 111 In-DTPA-octreotide (B) revealed metastases in the chest and thoracic spine.
Results
Baseline characteristics and follow-up
The patients' characteristics are summarized in Neither patient nr 5 nor nr 6 had had a follow-up CT scan at time of death.
Patient nr 2 died 2 months after the last treatment course due to tumor progression causing pleural effusion and emboli seen on CT performed the day before she died. Shortly before she died, which is 5 months after the first treatment, a complete biochemical and radiological evaluation was performed.
Although the 6 month follow-up was not completed, we decided to use these data for further evaluation. Finally, in none of the patients was there a significant difference measured in tumor uptake between the first and last treatment measured on days 3 and 7.
Effect of [ ¹¹¹ In-DTPA]-octreotide therapy Effect related to Tg levels at 3 and 6 months follow-up
Four patients with initial Tg levels <1000 μg/l demonstrated biochemical stable disease at 6 months after the start of the treatment course. This effect was already observed 3 months after the first administration. An effect of increased TSH levels during follow-up compared to the initial levels was excluded (Tables   1 and 2 ). Three out of five patients with rather high Tg levels had a further increase, which was already observed at the 3 month time interval.
In Figure 2 , Tg levels are presented from before, during and up to 1 year after Six month follow-up after 111 In-DTPA-octreotide therapy 157 treatment. Because of the very skewed distribution, log Tg levels are reported.
Due to the lack of follow-up in patients 5 and 6, the Tg curves are not shown. In-octreotide therapy. † Results 5 months after the first therapy: these data were obtained shortly before she died. NA, not available; P, progression; S, stabilization. In-octreotide. Because of the skewed distribution of the Tg levels, log Tg levels were used. Symbols represent the nine surviving patients in the study.
Therapeutic effect based on follow-up CT and Tg levels at 6 months
No patient had a tumor reduction on CTscan. However, in four of the patients studied stable disease was seen on CT. These patients had also stable tumor markers (mean Tg level 275μg/l; range 76-744μg/l). Five patients had radiological progression after ¹¹¹ In-DTPA-octreotide therapy, of which three also had tumor marker progression. One of these three patients, nr 9, had received an adjusted dose because of sicklecell disease. The mean Tg level in this group was 180432 μg/l (range, 3900-749000 μg/l ). From these data it is concluded that, in small tumors, expressed by rather low Tg levels, an antiproliferative effect was observed. In two out of these five patients, dissociation was observed between biochemical and radiological response criteria, suggesting a metabolic but no anti-proliferative effect.
The number of patients was too limited to draw any conclusion with respect to the uptake score and the therapeutic effect.
Discussion
The purpose of this study was to determine the effect of treatment with high, fixed doses of ¹¹¹ In-octreotide in patients with progressive iodine non-responsive thyroid cancer. Two patients died during follow-up, which was due to a sepsis in one and an insulin overdose in the other. Only patients with rather low Tg levels (<1000 μg/l) demonstrated both a biochemical and radiological stable disease, which reflects the response of small tumors to such large treatment doses as used in the present study.
Prognosis and survival
Thyroid cancer is often a slow growing tumor with a very good long-term survival. Of the patients diagnosed with differentiated thyroid cancer, 5-20% will develop a local or regional recurrence or metastatic disease [2] . Therapy is still the same as that for initial disease: surgery and ¹³¹ I treatment. More recent reports have focused on the value of external beam radiotherapy in the management of locoregional advanced thyroid cancer. In four of the recently published studies [8;12;22-24] , it was shown that radiotherapy indeed significantly improved locoregional control in patients with pT4 tumors or lymph node involvement. In the study by Ford et al., even a possible dose response was found with a local recurrence rate of 63% and 18% for doses <50Gy and >54Gy, respectively [23] . However, in two studies it was shown that, despite a better local control by a combination of surgery and external irradiation, this strategy did not improve survival in patients with locally advanced disease. In these case series, locoregional radiotherapy revealed 5 and 10 year survival rates of 96%, whereas the results for patients without radiotherapy were 94% and 89%, respectively [8;24] .
In the presence of extensive metastasized disease the overall 5 year survival rates declines to 60-82%. In case of ¹³¹ I uptake in metastases, the reported 2, 5 and 10 year survival rates are 91%, 77% and 62%, respectively. In contrast, however, the survival rates are 55%, 16% and 11%, respectively, in the case of metastatic disease that lost its capability of ¹³¹ I uptake [25;26] . Patients with radioiodine non-responsive progressive disease can be treated with radiotherapy for recurrent neck disease or chemotherapy (adriamycin) for widely metastatic disease. Adriamycin, however, reveals a partial response in only 30-40% of patients [10] , but these studies were performed in selected patient groups.
These results support the necessity for early detection and treatment of recurrent thyroid cancer that does not concentrate radioiodine.
Somatostatin receptor therapy
The use of unlabeled somatostatin in the treatment of neuroendocrine tumors is well established and is based on its inhibitory effect on hormone production and its antagonistic effect with regard to tumor growth factors. Somatostatin binds to a family of G-protein-coupled receptors [14] . There are five subtypes (SST [1] [2] [3] [4] [5] and somatostatin binds to all five. However, due to its short half-life (approx. Internalization is receptor mediated and temperature dependent [14] . Of the receptor subtypes, SST 3 is the most efficient at internalization while SST 1 does not. Reubi et al. [32;33] have evaluated the affinity of various radiolabeled somatostatin analogues for the different somatostatin receptor subtypes. They found that although radiolabeling with ¹¹¹ In decreased the affinity of octreotide to somatostatin receptors by 10-fold, its affinity to these was still significant. So, ¹¹¹ In-octreotide still can be sufficiently internalized by tumor cells expressing In-DTPA-octreotide therapy seems to be related to the amount of ¹¹¹ In-DTPA-octreotide uptake by the tumor.
Response was 86% in patients with high uptake (=intense), 67% in patients with average uptake (=higher than liver) and 50% in patients with low uptake (=lower than/equal to liver). In contrast to this, in our patient population the response to ¹¹¹ In-DTPA-octreotide therapy was observed in patients with rather low uptake scores (scores 1 and 2). The number of patients studied, however, is too small to draw a definite conclusion.
Thyroglobulin levels and treatment effect
Caillou et al. [35] as well as Lazar et al. [36] investigated the expression of thyroid-tissue specific genes in normal thyroid tissue and in thyroid carcinoma tissue. Correlation was found between the expression of the hNIS gene (human sodium/iodine symporter gene) and the ability of the tumor to concentrate iodine. Expression of the Tg gene in thyroid cancer cells, though 2-fold to 300-fold less than in normal tissue, remained well preserved in later tumor stages, being absent only in undifferentiated cancer cells [37] . Whether this dissociation between tumor marker production and tumor growth, as observed in two patients in the present study, can be clarified by a further positive selection of poorly differentiated cancer cells is not clear yet. If this is the case, labelling octreotide with a beta emitter could increase the effectiveness of radiolabeled octreotide therapy. However, results of somatostatin receptor scintigraphy (SRS) reported by Baudin et al. [17] do not support this theory. Although not fully elucidated, an anti-metabolic effect is more likely in the present cases. This effect also has been observed in neuroendocrine tumors, which causes a relief in symptoms caused by increased hormone production [38] [39] [40] [41] . MBq. In all three patients radiographic progression could not be stopped, whereas only one patient had decreasing tumor marker production. Otte et al. Finally, more recent reports have focused on the use of retinoic acids, as proliferation inhibiting and differentiation inducing effects in thyroid cancer [48;49] . These acids exert their effects via receptors. It has been shown that retinoic acids in various thyroid cell lines regulate NIS expression. In particular, the messenger RNA encoding the NIS is upregulated by the retinoic acid stimulation. In former clinical pilot studies, 40-50% of the patients with poorly differentiated thyroid carcinomas lacking iodine uptake responded to treatment to retinoic acids with an increase of iodine uptake [50] [51] [52] . In theory, this redifferentiation process of advanced thyroid carcinomas by stimulating the hNIS expression makes tumors accessible for radioiodine therapy again. In a more recent clinical study, however, it could not be confirmed. Grûning et al. [12] , studied 25 patients who were treated with retinoic acids at 1 mg/kg for 3 months followed by ¹³¹ I. In two out of 14 patients with raised Tg levels but no ¹³¹ I uptake, a slightly improved uptake was seen. In three out of 11 patients with slight uptake a dosimetrically relevant improvement of uptake was seen. Of these five responders (20%), two were completely free of symptoms, one showed stable disease and two patients worsened. Retinoic acid gave improvement of ¹³¹ I uptake in metastases with low radioiodine uptake, but it did not appear to induce uptake in ¹³¹ I negative metastases. Consequently, despite the mild and reversible side effects, its therapeutic use as a single agent in the patients reported in the present study is debatable. A possible enhancement of the antiproliferative effect of retinoic acid by phenylacetate is still under study.
Radiolabeled octreotide therapy in thyroid cancer and future prospects
In a report by Eigelberger et al. [53] , it was shown that retinoic acid and phenylacetate alone inhibited growth in a follicular cell line to 16% and 35%, respectively, compared with controls, whereas the combination of the two inhibited growth to 60%. This effect is probably due to an upregulation of the retinoic acid receptor by phenylacetate. Although an improvement of 131 I uptake in iodine negative metastases due to this synergistic effect might be expected, its role in clinical practice is still unclear and needs further study.
